髋关节表面置换与28mm金属对金属全髋置换15年随机研究对比
该随机对照研究将203髋分配至28mm金属对金属全髋置换组(99髋)或髋关节表面置换组(104髋),平均随访15年。两组WOMAC评分、翻修率及并发症率总体相似,但无菌翻修生存率全髋组显著更高(97.4% vs 89.2%,p=0.033),表面置换组无脱位而全髋组有4例脱位。
要点
- 平均随访15年,两组总体翻修生存率无显著差异(p=0.292)。
- 无菌翻修生存率全髋组显著高于表面置换组(97.4% vs 89.2%,p=0.033)。
- 表面置换组无脱位,全髋组4例脱位(p=0.058),并发症类型不同。
核心结论
- 本研究所用特定表面置换与28mm金属对金属全髋植入物均显示良好的长期生存和功能。
- 两组总体并发症率和翻修率相似但类型不同,表面置换组无脱位而全髋组有4例脱位。
- 表面置换能更好地保留股骨骨量并重建生物力学,在经验丰富术者选用验证植入物时对特定患者可能仍有作用。
研究设计与样本
- 随机对照研究,共203髋随机分配至28mm金属对金属全髋置换组(99髋)或髋关节表面置换组(104髋)。
- 主要结局指标为WOMAC评分、翻修率和并发症率,同时评估影像学表现。
- 平均随访15年(范围14至16年),9例(4.4%)失访,15例(7.4%)死亡。
- 证据等级为治疗性I级。
主要发现
- 以任何原因翻修为终点,表面置换组Kaplan-Meier生存率为89.2%(95%CI 82.3%至96.1%),全髋组为94.2%(95%CI 89.3%至99.1%),p=0.292。
- 以无菌翻修为终点,全髋组Kaplan-Meier生存率显著更高(97.4% vs 89.2%,p=0.033)。
- 全髋组翻修原因包括感染3例、复发性脱位1例、金属碎屑不良反应(ARMD)1例;表面置换组翻修原因为ARMD 2例和股骨头松动7例。
- 表面置换组无脱位发生,全髋组发生4例脱位(p=0.058)。
- 两组WOMAC评分(表面置换组10.7 vs 全髋组8.8,p=0.749)、遗忘关节评分(87.1 vs 85.3,p=0.410)、UCLA活动评分(6.3 vs 6.4,p=0.189)及总体关节感知(p=0.251)均相似。
关键数值与推荐
- 以任何原因翻修为终点,表面置换组生存率89.2%(95%CI 82.3%至96.1%),全髋组94.2%(95%CI 89.3%至99.1%),p=0.292。
- 以无菌翻修为终点,全髋组生存率97.4%,表面置换组89.2%,p=0.033。
- 表面置换组脱位0例,全髋组4例,p=0.058。
- WOMAC评分表面置换组10.7、全髋组8.8,p=0.749;遗忘关节评分87.1 vs 85.3,p=0.410;UCLA活动评分6.3 vs 6.4,p=0.189。
临床怎么用
- 对于选择表面置换的特定患者,应由经验丰富术者操作并使用已验证的植入物。
- 表面置换可更好地保留股骨骨量并重建生物力学,但需注意股骨头松动和ARMD风险。
- 全髋置换组无菌翻修生存率更高,但需关注脱位风险;两组功能评分相似。
局限性
- 本研究结果仅适用于所采用的特定表面置换和28mm金属对金属全髋植入物。
- 平均随访15年期间9例(4.4%)失访、15例(7.4%)死亡,可能影响结局评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone stock conservation, hip anatomy preservation, and greater stability are among the promoted advantages of hip resurfacing (HR). However, the disappointing failure of some implants nearly led to its abandonment. The aim of this study was to compare clinical scores and revision and complication rates after HR with those after total hip arthroplasty (THA). METHODS: Two hundred and three hips were randomized to 28-mm metal-on-metal (MoM) THA (99 hips) or to HR (104 hips). Main outcome measures compared between groups were the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, the revision rate, and the complication rates. The radiographic findings were also assessed. RESULTS: After a mean follow-up of 15 years (range, 14 to 16 years), 9 (4.4%) of the 203 patients were lost to follow-up and 15 (7.4%) had died. The Kaplan-Meier survivorship, with revision for any reason as the end point, was 89.2% (95% confidence interval [CI], 82.3% to 96.1%) for HR and 94.2% (95% CI, 89.3% to 99.1%) for THA (p = 0.292). The reasons for revision included infection (3 patients), recurrent dislocation (1 patient), and adverse reaction to metal debris (ARMD) (1 patient) in the THA group and ARMD (2 patients) and femoral head loosening (7 patients) in the HR group. With aseptic revision as the end point, the Kaplan-Meier survivorship was significantly higher in the THA group (97.4% versus 89.2%; p = 0.033). No dislocation occurred in the HR group compared with 4 in the THA group (p = 0.058). Both groups achieved a similar mean WOMAC score (10.7 in the HR group and 8.8 in the THA group; p = 0.749), Forgotten Joint Score (87.1 and 85.3, respectively; p = 0.410), University of California Los Angeles (UCLA) activity score (6.3 and 6.4, respectively; p = 0.189), and overall joint perception (p = 0.251). CONCLUSIONS: The specific HR and MoM 28-mm THA implants used in this study showed good long-term survival and function. The overall rates of complications and revisions were similar in both groups but were of different types. As it provides better femoral bone preservation and biomechanical reconstruction, HR may continue to have a role in selected patients when performed by experienced surgeons and using validated implants. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
引用
- Vendittoli PA, Shahin M, Rivière C, et al. Hip Resurfacing Compared with 28-mm Metal-on-Metal Total Hip Replacement: A Randomized Study with 15 Years of Follow-up. J Bone Joint Surg Am. 2020. PMID: 32554999. doi:10.2106/JBJS.20.00030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。